FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
About this publication
Authors: Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., Gillett, C., Grigoriadis, A., Tutt, A., Reis-Filho, J. S., Ashworth, A.
Publication reference: Cancer Res, 70, 2085-2094.
